在Everolimus治疗的固体瘤患者中,肝炎和乙型肝炎病毒的重新激活:关注HBV流行地区
Chien-Hao Su1,2, Chung-Yu Chen1, Chien-Ting Liu3
1School of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Cancers
|December 17, 2024
概括
治疗Everolimus具有B型肝炎病毒 (HBV) 再激活 (HBVr) 和肝炎的显著风险,特别是在HBsAg阳性患者中. 密切监测肝功能和HBV状态对于接受everolimus治疗的癌症患者至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 病毒学 病毒学
背景情况:
- 埃弗罗利斯是一种mTOR抑制剂,用于治疗乳腺癌,癌和神经内分泌癌症.
- 乙型肝炎病毒的重新激活 (HBVr) 是与免疫抑制疗法相关的已知风险.
- 关于HBVr的数据有限,特别是在接受everolimus治疗的患者中.
研究的目的:
- 为了评估肝炎和HBVr的发病率和风险,在接受everolimus的癌症患者当前或过去感染乙型肝炎病毒 (HBV) 的癌症患者.
- 在这个患者群体中识别与肝炎和HBVr相关的风险因素.
主要方法:
- 从2011年1月到2022年5月在台湾接受治疗的377名癌症患者的回顾性分析.
- 纳入标准:具有HBsAg阳性或HBsAg阴性,具有抗HBs或抗HBc结果的患者.
- 分析使用累积发病率函数和竞争风险模型 (细灰SDH) 来评估肝炎风险和HBVr.
主要成果:
- 肝炎发生在28.75%的HBsAg阳性患者和17.85%的HBsAg阴性患者中.
- 在没有核胺类同类 (NUCs) 预防的HBsAg阳性患者中,HBVr被观察到11.36%,在预防的患者中,HBsAg阳性患者中,HBvr被观察到5.56%.
- 基线HBsAg阳性和埃克塞梅斯坦使用与肝炎风险增加有关;两个HBsAg阴性,抗HBc阳性患者患有严重的HBVr相关肝炎.
结论:
- 埃弗罗利莫斯治疗与肝炎和HBVr的重大风险有关,特别是在HBsAg阳性个体中.
- 乙型肝炎病毒较少见,但仍在 HBsAg 阴性,先前暴露于 HBV (抗-HBc 阳性) 的患者中引起关注.
- 常规的HBV查和警的肝功能监测对于所有癌症患者来说是必不可少的Everolimus当前或过去的HBV感染,特别是在HBV流行地区.
关键词:
乙型肝炎病毒流行地区.药物诱导性肝损伤 (DILI) 是一种药物诱导性肝损伤.这是Everolimus.肝炎肝炎是什么意思 肝炎肝炎是什么意思乙型肝炎的重新激活免疫抑制是一种免疫抑制.固体瘤是一种固体瘤.更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.8K
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
381
相关概念视频
Mechanisms of Retrovirus-induced Cancers
5.2K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.2K
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Pulmonary Tuberculosis I
1.7K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.7K
Hepatitis
99
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
99
Viral Hepatitis I: Introduction
28
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
28
